why would someone with such a massive reputation want to join the PYC board.....mmm this is now looking interesting.
FORMER PFIZER VICE-PRESIDENT OF CLINICAL RESEARCH JOINS PHYLOGICA BOARD Perth, 21 February 2007 Phylogica Limited (ASX:PYC) announced today that Dr Mark Pierce M.D. Ph.D., the former Senior Vice President of Clinical Research at Pfizer, Inc. (the world’s largest pharmaceutical company with revenues over US$50 billion), had been appointed as a non-executive Director of Phylogica. Dr Pierce, who serves on a number of biotechnology company boards, has a distinguished career in the pharmaceutical industry. He graduated from Northwestern University Medical School in Chicago and received his postgraduate training in internal medicine at the Peter Bent Brigham Hospital and Massachusetts General Hospital in Boston. Subsequently, he was Senior Vice President of Clinical Research at Pfizer, after directing clinical development at Abbott Laboratories and Warner Lambert Company. “Dr Pierce brings a wealth of international drug development experience and major pharmaceutical industry networks to Phylogica. This will open new doors to pharmaceutical company clients for our drugs and technology and add significant momentum to realising the value of Phylogica. ” said Phylogica CEO, Dr Stewart Washer. “We are confident Dr Pierce’s experience and contacts will be invaluable at this critical expansion stage as Phylogica continues to develop new relationships with international biotechnology and pharmaceutical companies and expand on our current deals with Opsona Therapeutics and Johnson & Johnson Research,” added Dr Washer. “I am delighted to have been asked to join the Phylogica Board of Directors, “ said Dr Pierce. “The company has a world-class drug discovery engine that has been validated by the commercialisation deals it has consummated so far, and I look forward to contributing to the future development of the company, its technology and its products,” added Dr Pierce.
PYC Price at posting:
0.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)